Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Fiche publication

Date publication

mai 2019

Journal

Clinical colorectal cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Pr BORG Christophe , Pr CONROY Thierry , Pr GHIRINGHELLI François , Pr MANTION Georges , Dr SPAETH Dominique , Dr LAKKIS Zaher

Tous les auteurs :
Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31311761

Résumé

Recurrence and distant metastases remain a significant issue in locally advanced rectal cancer (LARC). Several multimodal strategies are assessed in clinical trials.